Key resistance biomarkers in prostate cancer, such as AR alterations, are acquired over time. This means that a biomarker test performed at initial diagnosis in the hormone-sensitive stage (MHSPC) is not sufficient for guiding therapy decisions in the castrate-resistant (CRPC) setting.
When prostate cancer transforms to a neuroendocrine phenotype, there is no standard treatment protocol. Clinicians experiment with various combinations like platinum chemo with taxanes or immunotherapy, but lack consensus, indicating a significant knowledge gap and a desperate search for effective options.
Experts admit to preferring docetaxel chemotherapy over lutetium for symptomatic mCRPC patients primarily because it 'feels' more aggressive and is logistically faster to administer. This decision is based on perception and convenience rather than strong clinical evidence comparing the agents in this specific context.
Patients with BRCA-mutated prostate cancer who progress on first-line PARP inhibitors have very poor options. Standard therapies like docetaxel are largely ineffective, and emerging data suggests cross-resistance with Lutetium, creating a significant unmet clinical need for novel approaches.
Despite his study showing an overall survival signal favoring docetaxel, lead author Dr. Kim Chi attributes this to crossover bias where patients avoided chemotherapy. He personally favors lutetium first due to its superior tolerability, contradicting the panel's majority opinion.